The US Food and Drug Administration (FDA) has issued an early alert over a ‘potentially high-risk’ issue with certain Baxter ...

The FDA today issued a notice warning of a potential high-risk issue with certain Baxter Spectrum infusion pump systems.

Baxter Healthcare has issued a recall for some Spectrum infusion pumps due to a potential defect involving missing motor mounting screws, which could lead to interruptions, delays or incorrect dosing ...

Baxter International ended 2024 on a positive note, overcoming challenges posed by Hurricane Helene and delivering better-than-expected Q4 results. The success of the Novum IQ infusion pump ...

Continuing operations exclude Baxter’s Kidney Care business ... product portfolio driven by robust sales for the Novum IQ infusion pump, increased sales of parenteral nutrition products and ...

New products like the Novum IQ infusion pump platform should help sales expand. On the bottom line in 2025, Baxter aims to generate $2.45 to $2.55 of adjusted EPS, which is slightly above our ...

Successful launch of Novum IQ infusion pump and 50% growth in infusion business. Positive 2025 guidance with expected sales growth of 5-6%. Baxter International demonstrated solid performance in ...